BTIG analyst Thomas Shrader reiterated a Neutral rating on Biogen (NASDAQ: BIIB).The analyst comments "In Biogen's recent guidance to analysts ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE